|RxNews Recap for 05-13-11|
|By BioMedReports.com Staff|
|Friday, 13 May 2011 18:39|
Access Plans, Inc. (OTCBB: APNC), a leading membership benefits marketing company, today announced record operating results for the second quarter and first half of FY2011.
Adherex Technologies Inc. (TSX:AHX) (PINK SHEETS:ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today reported its financial results and recent developments for the first quarter ended March 31, 2011.
Amgen (NASDAQ:AMGN) will webcast its investor meeting at the upcoming American Urological Association (AUA) Conference on Tuesday, May 17 at 12:00 p.m. Eastern Time.
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced the appointment of Robert Chisholm to the Board of Directors.
Biodel Inc. (Nasdaq:BIOD) today announced that it has entered into definitive agreements with a group of institutional investors, including Great Point Partners, LLC and Orbimed Advisors, LLC, to sell approximately 12.2 million shares of its common stock, 1.7 million shares of its Series A Convertible Preferred Stock and warrants to purchase 9.0 million shares of its common stock.
Daxor Corporation (NYSE Amex: DXR), Three Months Ended March 31, 2011 March 31, 2010.
Leatt Corporation, a Nevada corporation (PINKSHEETS: LEAT) (Company), and the distributor of the Leatt-Brace®, a Neck Brace System designed to help prevent potentially devastating motor sport injuries to the cervical spine (neck), today announced unaudited financial results for the first fiscal quarter ended March 31, 2011, ("Q1 FY2011").
MedeFile International, Inc. (OTCQB: MDFI) (PINKSHEETS: MDFI), a leader in Internet-enabled Personal Health Record (iPHR) management solutions, today announced that the Company's Chairman, President and CEO, Kevin Hauser, will be featured on CBS 12 News (WPEC NEWS 12), airing tonight at 11:00 PM Eastern Time.
Molecular Insight Pharmaceuticals, Inc. (OTCQB: MIPIQ) (PINKSHEETS: MIPIQ), today announced that it has filed Form 15 with the Securities Exchange Commission (the "SEC") to deregister its common stock and common stock purchase rights, which are attached to and traded with shares of the common stock, under the Securities Exchange Act of 1934, as amended, and to suspend its reporting obligations thereunder.
Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for disorders of the brain and central nervous system, today announced its financial results for the three months ended March 31, 2011.
Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Frederick Driscoll, Chief Financial Officer of Novavax, will be presenting at the NOBLE FINANCIAL 7th Annual Equity Conference on May 16, 2011 at 10:30am at The Hard Rock Hotel, Hollywood, FL.
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") reports a correction of a formatting error in its first quarter news release issued on May 12, 2011.
ProPhase Labs (NASDAQ: PRPH) www.ProPhaseLabs.com today reported net sales of $3.2 million for the three months ended March 31, 2011, compared to net sales of $2.0 million for the three months ended March 31, 2010.
Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a developer and global marketer of In Vitro Diagnostic (IVD) cancer diagnostic tests, today announced it has filed an 8K with the Securities and Exchange Commission ("SEC") reporting an event of default has occurred, which has caused the balance of the Convertible Promissory Notes ("Notes") RPC issued in the first quarter FY2011 to increase and become immediately due and payable.
Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2011.
Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2011.
Spherix Incorporated (NASDAQ: SPEXD) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today reported financial results for the three months ended March 31, 2011.
Therma-Med, Inc. (PINKSHEETS: THRA) ("the Company") would like to apprise its shareholders of current corporate events.